Monocyte suppressing action of fenofibrate

Pharmacological Reports

Volumn 57, Issue 3, 2005, Pages 367-372

  Okopień, Bogusław ^a   Kowalski, Jan ^a   Krysiak, Robert ^a   Łabuzek, Krzysztof ^a   Stachura Kułach, Aldona ^a   Kułach, Andrzej ^a   Zieliński, Marek ^a   Herman, Zbigniew S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Atherosclerosis; Dyslipidemia; Fibrate; Monocyte; Proinflammatory cytokines

Indexed keywords

FENOFIBRATE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LOW FAT DIET; MALE; MONOCYTE; PROTEIN BLOOD LEVEL;

EID: 22744457125     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, Smith CW et al.: Soluble cell adhesion molecules in hypertrigliceridemia and potential significance of monocyte adhesion. Arterioscler Thromb Vasc Biol, 1998, 18, 723-731.
2. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA, 2001, 285, 2486-2497.
3. Arts J, Kockx M, Princen HM, Kooistra T: Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler Thromb Vasc Biol, 1996, 17, 26-32.
4. Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-κB reduces MMP-1, 3 and 9 production by vascular smooth muscle cells. Cardiovasc Res, 2001, 50, 556-565.
5. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-mice reveals a role of chemokines in initiation of atherosclerosis. Nature, 1998, 394, 894-897.
6. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator activated receptors (PPARs), nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res, 2000, 49, 497-505.
7. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC et al.: Peroxisome proliferator activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem, 1999, 274, 32048-32054.
8. Dinarello C: Biologic basis for interleukin-1 in disease. Blood, 1996, 87, 2095-2147.
9. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z et al.: Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J Biol Chem, 2002, 277, 48051-48057.
10. Flo RW, Naess A, Lund-Johansen F, Maehle BO, Sjursen H, Lehmann V, Solberg CO: Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies. J Immunol Methods, 1991, 137, 69-94.
11. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ et al.: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest, 1999, 103, 773-778.
12. Greenwald RA: Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Ann NY Acad Sci, 1999, 878, 413-419.
13. Gutstein DE, Fuster V: Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res, 1999, 41, 323-333.
14. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr et al.: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation, 1996, 93, 1334-1338.
15. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T: Fibrates down-regulate IL1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50 NF-κB-C /EBP-β complex formation. Blood, 2003, 101, 545-551.
16. Kowalski J, Okopień B, Madej A, Makowiecka K, Zielinski M, Kalina Z, Herman ZS: Levels of sICAM-1 sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa and IIb. Int J Clin Pharmacol Ther, 2001, 39, 48-52.
17. Kowalski J, Okopień B, Madej A, Zielinski M, Belowski D, Kalina Z, Herman ZS: Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. Eur J Clin Pharmacol, 2003, 59, 189-193.
18. Kowalski J, Okopień R, Madej A, Zielinski M, Belowski D, Kalina Z, Herman ZS: Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther, 2003, 41, 241-247.
19. Kraemer R: Regulation of cell migration in atherosclerosis. Curr Atheroscler Rep, 2000, 2, 445-452.
20. Libby P: Managing the risk of atherosclerosis, the role of high-density lipoproteins. Am J Cardiol, 2001, 88, Suppl, 3N-8N.
21. Libby P, Ridker P: Novel inflammatory markers of coronary risk. Circulation, 1999, 100, 1148-1150.
22. O'Brien K, Chait A: The biology of the artery wall in atherogenesis. Lipid Disorders, 1994, 78, 41-67.
23. Okopień B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wiśniewska-Wanat M, Kalina Z et al.: Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther, 2001, 39, 551-557.
24. Ross R: Atherosclerosis - an inflammatory disease. N Eng J Med, 1999, 340, 115-126.
25. Schoonjans K, Steals B, Auwerx J: Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res, 1996, 37, 907-925.
26. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, Wright SD et al.: Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun, 2000, 267, 345-349.
27. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998, 98, 2088-2093.
28. Steinberg D, Lewis A: Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation, 1997, 95, 1062-1071.
29. Takahashi M, Masuyama J, Ikeda U, Kasahara T, Kitagawa S, Takahashi Y, Shimada K et al.: Induction of monocyte chemotactic protein 1 synthesis in human monocytes during transendothelial migration in vitro. Circ Res, 1991, 76, 750-757.
30. Weber C, Erl W, Weber KS, Weber PC: Effect of oxidized LDL, lipid mediators and statins on vascular cell interaction. Clin Chem Lab Med, 1999, 37, 243-251.